In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on InflaRx (IFRX – Research Report). The company’s shares closed today at $1.20.
Slutsky covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Astria Therapeutics, and Cogent Biosciences. According to TipRanks, Slutsky has an average return of 14.6% and a 48.33% success rate on recommended stocks.
Currently, the analyst consensus on InflaRx is a Moderate Buy with an average price target of $6.50.
IFRX market cap is currently $73.02M and has a P/E ratio of -1.46.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
InflaRx (IFRX) Company Description:
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
